Adding FISH to karyotype in Myelodysplastic syndrome investigation diagnosis: Are all questions answered?

Leukemia Research

Volumn 34, Issue 4, 2010, Pages 413-415

  Chauffaille, Maria de Lourdes L F ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; BACTERIAL ARTIFICIAL CHROMOSOME; CANCER GRADING; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; EDITORIAL; EVENT FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC RISK; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; KARYOTYPING; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

AGED; DECISION SUPPORT TECHNIQUES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 77049125933     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.10.011     Document Type: Editorial

References (22)

1. Corey S.J., Minden M.D., Barber D.L., Kantarjian H., Wang J.C.Y., and Schimmer A.D. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev/Cancer 7 (2007) 118-129
2. Lorand-Metze I., Pinheiro M.P., Ribeiro E., Paula E.V., and Metze K. Factors influencing survival in Myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. Leuk Res 28 (2004) 587-594
3. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the Myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
4. In: Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., and Vardiman J.W. (Eds). WHO Classification of tumours and lymphoid tissues (2008), IARC Lyon
5. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in Myelodysplastic syndromes. Blood 89 (1997) 2079-2088
6. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in Myelodysplastic syndromes. J Clin Oncol 25 (2007) 3503-3510
7. Malcovati L., and Nimer S.D. Myelodysplastic syndromes: diagnosis and staging. Cancer Control 15 suppl. 4-13 (2008)
8. Solé F., Luño E., Sanzo C., Espinet B., Sanz G.F., Cervera J., et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary Myelodysplastic syndromes. Haematologica 90 (2005) 1168-1178
9. Haase D. Cytogenetics features in Myelodysplastic syndromes. Ann Hematol 87 (2008) 515-526
10. Valent P., Horny H.P., Bennett J.M., Fonatsch C., Germing U., Greenberg P., et al. Definitions and standards in the diagnosis and treatment of the Myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 31 6 (2007) 727-736
11. ISCN. In: Shaffer L.G., Slovak M.L., and Campbell L.J. (Eds). An international system for human cytogenetics nomenclature (2009), S. Karger, Basel
12. Bernasconi P., Boni M., Cavigliano P.M., Calatroni S., Giardini I., Rocca B., et al. Clinical relevance of cytogenetics in Myelodysplastic syndromes. Ann N Y Acad Sci 1089 (2006) 395-410
13. Wiktor A.E., Van Dyke D.L., Stupca P.J., Ketterling R.P., Thorland E.C., Shearer B.M., et al. Preclinical validation of fluorescence in situ hybridization assays for clinical practice. Genet Med 8 1 (2006) 16-23
14. Romeo M., Chauffaille M.L.L.F., Silva M.R.R., Bahia D.M., and Kerbauy J. Comparison of cytogenetics with FISH in 40 Myelodysplastic syndrome patients. Leuk Res 26 11 (2002) 993-996
15. Panani A.D., and Pappa V. Hidden chromosome 8 abnormalities detected by FISH in adults primary Myelodysplastic syndromes. In Vivo 19 6 (2005) 979-981
16. Rigolin G.M., Bigoni R., Milani R., Cavazzini F., Roberti M.G., Bardi A., et al. Clinical importance of interphase cytogenetics detecting occult chromosome lesions in Myelodysplastic syndromes with normal karyotype. Leukemia 15 12 (2001) 1841-1847
17. Bernasconi P., Cavilgiano P.M., Boni M., Calatroni S., Giardini I., Rocca B., et al. Is FISH a relevant prognostic tool in Myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients. Leukemia 17 (2003) 2107-2112
18. Cherry A.M., Brockman S.R., Paternoster S.F., Hicks G.A., Neuberg D., Higgins R.R., et al. Comparison of interphase FISH and metaphase cytogenetics to study Myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. Leuk Res 27 12 (2003) 1085-1090
19. Pinheiro R.F., and Chauffaille M.L.L.F. Comparison of I-FISH and G-banding for the detection of chromosomal abnormalities during the evolution of Myelodysplastic syndrome. Braz J Med Biol Res 42 11 (2009) 1110-1112
20. Steema D.P., and List A.F. Genetic testing in the Myelodysplastic syndromes. Mayo Clin Proc 80 5 (2005) 681-698
21. Slovak M.L., and Dewald G.W. International Working group on Myelodysplastic syndrome cytogenetics, Oct 2007 Meeting. Report Leuk Res 32 (2008) 1329-1332
22. Maciejewski J.P., and Mufti G.J. Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood 112 (2008) 974-985